Your session is about to expire
← Back to Search
Neural crest tumors and sympathetically innervated organs undergoing tissue sampling for Neuroblastoma
Study Summary
This trial is studying the relationship between a type of imaging called 18F-mIBG positron emission tomography (PET) and a transporter in the body called norepinephrine transporter.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current number of individuals being recruited for participation in this clinical study?
"Indeed, the information available on clinicaltrials.gov indicates that this ongoing clinical trial is actively seeking eligible participants. The study was initially posted on September 14th, 2023 and underwent its most recent update on January 30th, 2024. Recruitment for this study aims to enroll a total of 29 patients from a single research site."
Are potential participants currently able to apply for this ongoing medical study?
"Indeed, as per the details available on clinicaltrials.gov, this research is presently seeking suitable candidates. The initial posting of this clinical trial was made on September 14th, 2023, and it has been recently updated on January 30th, 2024. This study aims to enroll a total of 29 participants across a single designated site."
What are the main goals being pursued in this research endeavor?
"The primary objective of this study is to measure the uptake of 18F-mFBG in sampled tissue, with tissue sampling completed within 22 days of imaging. Secondary outcomes include evaluating the quality implications of reducing the administered activity of 18F-mFBG and comparing disease detection at 60 minutes between different imaging methods. The image data files and processed PET images will undergo blinding and randomization before being qualitatively examined by three independent readers who are unaware of the clinical status but have access to cross-sectional images (CT or MRI) acquired during the PET exam. Additionally, adverse events occurring in subjects with neuroblastoma will be"
What is the level of safety associated with obtaining tissue samples from neural crest tumors and sympathetically innervated organs in individuals?
"The safety of Neural crest tumors and sympathetically innervated organs undergoing tissue sampling is estimated to be a 2 on a scale from 1 to 3. This evaluation corresponds to the Phase 2 trial, which has limited data supporting safety but no evidence yet for efficacy."
Share this study with friends
Copy Link
Messenger